Genome-wide characterization of TAZ binding sites in mammary epithelial cells in temporary and special manner (ATAC-seq)
Ontology highlight
ABSTRACT: TAZ, one of the key components of Hippo signaling pathway, is a transcription coactivator and plays an important role in cell proliferation, anti-apoptosis, therapeutic resistance, cancer stemness and tumorigenesis. TAZ mediated transcription program through transcription factors, such as TEAD family members. Genome-wide TAZ occupancy is poorly defined. Here, using a tet-inducible TAZ activation in mammary epithelial MCF10A cells, we characterized genome-wide binding sites in different TAZ activation time points. We found vast majority of TAZ binds to distal enhancer and intergenic regions of genes in the early TAZ activation time point and shift to promoter regions in the later TAZ activation time point. We identified three distinctive TAZ binding patterns to its targets. Furthermore, we found TAZ activation results in chromatin architecture alterations. Our studies provide insight of TAZ regulated transcription program in mammary epithelial cells and indicate potential therapeutic targets for breast cancer.
Project description:TAZ, one of the key components of Hippo signaling pathway, is a transcription coactivator and plays an important role in cell proliferation, anti-apoptosis, therapeutic resistance, cancer stemness and tumorigenesis. TAZ mediated transcription program through transcription factors, such as TEAD family members. Genome-wide TAZ occupancy is poorly defined. Here, using a tet-inducible TAZ activation in mammary epithelial MCF10A cells, we characterized genome-wide binding sites in different TAZ activation time points. We found vast majority of TAZ binds to distal enhancer and intergenic regions of genes in the early TAZ activation time point and shift to promoter regions in the later TAZ activation time point. We identified three distinctive TAZ binding patterns to its targets. Furthermore, we found TAZ activation results in chromatin architecture alterations. Our studies provide insight of TAZ regulated transcription program in mammary epithelial cells and indicate potential therapeutic targets for breast cancer.
Project description:TAZ, one of the key components of Hippo signaling pathway, is a transcription coactivator and plays an important role in cell proliferation, anti-apoptosis, therapeutic resistance, cancer stemness and tumorigenesis. TAZ mediated transcription program through transcription factors, such as TEAD family members. Genome-wide TAZ occupancy is poorly defined. Here, using a tet-inducible TAZ activation in mammary epithelial MCF10A cells, we characterized genome-wide binding sites in different TAZ activation time points. We found vast majority of TAZ binds to distal enhancer and intergenic regions of genes in the early TAZ activation time point and shift to promoter regions in the later TAZ activation time point. We identified three distinctive TAZ binding patterns to its targets. Furthermore, we found TAZ activation results in chromatin architecture alterations. Our studies provide insight of TAZ regulated transcription program in mammary epithelial cells and indicate potential therapeutic targets for breast cancer.
Project description:In several developmental lineages, an increase in expression of the MYC proto-oncogene drives the transition from quiescent stem cells to transit amplifying cells. The mechanism by which MYC restricts self-renewal of adult stem cells is unknown. Here, we show that MYC activates a stereotypic transcriptional program of genes involved in protein translation and mitochondrial biogenesis in mammary epithelial cells and indirectly inhibits the YAP/TAZ co-activators that are essential for mammary stem cell self-renewal. We identify a phospholipase of the mitochondrial outer membrane, PLD6, as the mediator of MYC activity. PLD6 mediates a change in the mitochondrial fusion/fission balance that promotes nuclear export of YAP/TAZ in a LATS- and RHO-independent manner. Mouse models and human pathological data confirm that MYC suppresses YAP/TAZ activity in mammary tumors. PLD6 is also required for glutaminolysis, arguing that MYC-dependent changes in mitochondrial dynamics balance cellular energy metabolism with the self-renewal potential of adult stem cells. ChIP-Seq experiments for MYC-HA (HA-IP) performed in IMEC primary breast epithelial cells. Input-samples were sequenced as controlls.
Project description:Basal breast cancers, an aggressive breast cancer subtype that has poor treatment options, are thought to arise from luminal mammary epithelial cells that undergo basal-like plasticity through poorly understood mechanisms. Using genetic mouse models and ex vivo primary organoid cultures, we show that conditional co-deletion of the LATS1 and LATS2 kinases, key effectors of Hippo pathway signaling, in mature mammary luminal epithelial cells promotes the development of basal-like carcinomas that metastasize over time. Genetic co-deletion experiments revealed that phenotypes resulting from the loss of LATS1/2 activity are dependent on the transcriptional regulators YAP/TAZ. Notably, transcriptional analyses of LATS1/2-deleted mammary epithelial cells revealed a gene expression program that associates with human basal breast cancers. Our study demonstrates in vivo roles for the LATS1/2 kinases in mammary epithelial homeostasis and luminal-basal fate control and implicates signaling networks induced upon the loss of LATS1/2 activity in the development of basal breast cancers.
Project description:In several developmental lineages, an increase in expression of the MYC proto-oncogene drives the transition from quiescent stem cells to transit amplifying cells. The mechanism by which MYC restricts self-renewal of adult stem cells is unknown. Here, we show that MYC activates a stereotypic transcriptional program of genes involved in protein translation and mitochondrial biogenesis in mammary epithelial cells and indirectly inhibits the YAP/TAZ co-activators that are essential for mammary stem cell self-renewal. We identify a phospholipase of the mitochondrial outer membrane, PLD6, as the mediator of MYC activity. PLD6 mediates a change in the mitochondrial fusion/fission balance that promotes nuclear export of YAP/TAZ in a LATS- and RHO-independent manner. Mouse models and human pathological data confirm that MYC suppresses YAP/TAZ activity in mammary tumors. PLD6 is also required for glutaminolysis, arguing that MYC-dependent changes in mitochondrial dynamics balance cellular energy metabolism with the self-renewal potential of adult stem cells. RNA-Seq Experiments in 2 different primary breast epithelial cell lines (HMLE, which were sorted according to CD44/CD24 surface markers & unsorted IMEC). Both cell lines expressed a doxycycline-inducible version of MYC. For the HMLE cell line DGE analysis was performed for the uninduced (EtOH) situation, comparing CD44high vs CD44 low and for the induced situation Dox vs. EtOH for the CD44high population. For the IMEC cell line DGE was performed by comparing Dox-treated populations expressing either Dox-inducible MYC or a vector control which allows to filter out potential effects due to doxycycline treatment.
Project description:In several developmental lineages, an increase in expression of the MYC proto-oncogene drives the transition from quiescent stem cells to transit amplifying cells. The mechanism by which MYC restricts self-renewal of adult stem cells is unknown. Here, we show that MYC activates a stereotypic transcriptional program of genes involved in protein translation and mitochondrial biogenesis in mammary epithelial cells and indirectly inhibits the YAP/TAZ co-activators that are essential for mammary stem cell self-renewal. We identify a phospholipase of the mitochondrial outer membrane, PLD6, as the mediator of MYC activity. PLD6 mediates a change in the mitochondrial fusion/fission balance that promotes nuclear export of YAP/TAZ in a LATS- and RHO-independent manner. Mouse models and human pathological data confirm that MYC suppresses YAP/TAZ activity in mammary tumors. PLD6 is also required for glutaminolysis, arguing that MYC-dependent changes in mitochondrial dynamics balance cellular energy metabolism with the self-renewal potential of adult stem cells.
Project description:In several developmental lineages, an increase in expression of the MYC proto-oncogene drives the transition from quiescent stem cells to transit amplifying cells. The mechanism by which MYC restricts self-renewal of adult stem cells is unknown. Here, we show that MYC activates a stereotypic transcriptional program of genes involved in protein translation and mitochondrial biogenesis in mammary epithelial cells and indirectly inhibits the YAP/TAZ co-activators that are essential for mammary stem cell self-renewal. We identify a phospholipase of the mitochondrial outer membrane, PLD6, as the mediator of MYC activity. PLD6 mediates a change in the mitochondrial fusion/fission balance that promotes nuclear export of YAP/TAZ in a LATS- and RHO-independent manner. Mouse models and human pathological data confirm that MYC suppresses YAP/TAZ activity in mammary tumors. PLD6 is also required for glutaminolysis, arguing that MYC-dependent changes in mitochondrial dynamics balance cellular energy metabolism with the self-renewal potential of adult stem cells.